A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Upper Tract Urothelial Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients
Detailed description
Although Upper Tract Urothelial Carcinoma (UTUC) is relatively uncommon, the incidence rate is increasing. There are many controversies and limitations in the management of Upper Tract Urothelial cancer.
In this study, investigators would like to establish a local registry for upper tract urothelial cancer to facilitate the collection of clinical information and outcomes of upper tract urothelial cancer management, and to collect blood, urine and tumour tissue samples to investigate for new diagnostic and therapeutic agents. Hopefully, our registry can provide information regarding the epidemiology, natural history, and treatment outcomes of upper tract urothelial cancer in Hong Kong.
Primary outcome measures
- Long-term survival [Time frame: 10 years]
Secondary outcome measures (3)
- Recurrence rate of UTUC [Time frame: 10 years]
- Progression rate of UTUC [Time frame: 10 years]
- Complications [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Male patients > 18 years old
- Patients who has presence of UTUC and pending for surgery
- Patients who has history of UTUC with any intervention performed
Exclusion criteria
\- Patients fail to provide informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Hong Kong · 1 center
- Prince of Wales Hospital — Hong Kong
Publications
- Cauberg EC, Salomons MA, Kummerlin IP, de Reijke TM, Zwinderman AH, de la Rosette JJ, Kate FJ, Laguna Pes MP. Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of PALGA, the Dutch national histopathology registry. BJU Int. 2010 Apr;105(7):922-7. doi: 10.1111/j.1464-410X.2009.08889.x. Epub 2009 Oct 5. PMID 19804428
- Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012 Jul;62(1):100-14. doi: 10.1016/j.eururo.2012.02.030. Epub 2012 Feb 23. PMID 22381168
- Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH. Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark 1943-88. Scand J Urol Nephrol. 1993;27(3):327-32. doi: 10.3109/00365599309180442. PMID 8290911
- Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000 Nov;164(5):1523-5. PMID 11025695
- Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C. Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol. 2011 Apr;3(2):69-80. doi: 10.1177/1756287211403349. PMID 21869907
Identifiers
NCT: NCT05438537 · CRE 2020.484